Even on the lowest dose of 'triple G' drug patients lost nearly 30 pounds

Key Points:

• Retatrutide, a novel weight loss drug targeting three metabolic receptors (GLP-1, GIP, and glucagon), is nearing FDA approval and has shown significant weight loss results in Phase 3 trials, with participants losing up to 20.8% of their body weight on the highest dose over 80 weeks.
• The drug also effectively lowers blood sugar levels (A1C), with reductions averaging 1.4% on the lowest dose and additional decreases at higher doses, benefiting patients with type 2 diabetes and obesity.
• Retatrutide improves heart health markers by significantly reducing triglycerides, cholesterol, blood pressure, waist circumference, and inflammation indicators, potentially lowering risks for heart disease and stroke.
• Common side effects include gastrointestinal issues such as diarrhea, nausea, constipation, decreased appetite, and vomiting, with higher doses increasing their frequency; neurological symptoms like dyesthesia and urinary tract infections were also reported but were generally mild to moderate and resolved during treatment.
• Despite its unapproved status, demand for retatrutide has led to a surge in counterfeit versions on the gray market, prompting Eli Lilly to initiate lawsuits against knockoff producers.